Cyp2c9 Genotyping
CYP2C9 Genotyping is a pharmacogenetic testing method that identifies genetic variants in the CYP2C9 gene to predict an individual’s metabolic capacity for certain drugs, particularly oral anticoagulants and nonsteroidal anti-inflammatory drugs.
764
Publications
49.1K
Citations
4K
Authors
1.3K
Institutions
Publications per year
2017–2026
128
Variants
Cyp2c9 Genotype Testing
Parents
764
1–5 of 764
4K
20
h-index
15
h-index
15
h-index
15
h-index
15
h-index
1–5 of 4K
1.3K
University of Washington
Seattle, United States
25 h-index
114 publications
12.2K citations

Karolinska Institutet
Stockholm, Sweden
21 h-index
91 publications
11.9K citations

Karolinska University Hospital
Stockholm, Sweden
19 h-index
60 publications
6.8K citations
Sungkyunkwan University
Seoul, South Korea
17 h-index
147 publications
4.5K citations

Universidad de Extremadura
Badajoz, Spain
17 h-index
74 publications
5.1K citations
PharmacoGenetics (China)
Hong Kong, China
15 h-index
94 publications
3.7K citations
National Institute of Environmental Health Sciences
Durham, United States
15 h-index
35 publications
3.3K citations
University of Florida
Gainesville, United States
14 h-index
49 publications
7.5K citations
1–8 of 1.3K
CPT · 71 publications · 9.6K citations
53
h-index
45 publications · 2.2K citations
31
h-index
37 publications · 2.2K citations
28
h-index
28 publications · 4.3K citations
27
h-index
BJCP · 28 publications · 2.2K citations
24
h-index
1–5